## LIN: Linde plc - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%); PEG 1.93 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($415.98)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Linde (LIN) Stock News: Price, Analyst Forecasts, and Key Catalysts to Watch Ahead of the Next U.S. Trading Session**
- Source: ts2.tech | 20251228T195331 | Neutral | Relevance: 100%
- This article provides an overview of Linde plc (LIN) stock heading into the final trading days of 2025, focusing on its defensive industrial gas model versus persistent softness in European markets. It discusses the stock's current price, analyst forecasts, and key catalysts like holiday-shortened trading, economic indicators, and upcoming earnings. The summary emphasizes Linde's long-term investment appeal due to its contractual supply and pricing discipline, alongside risks like European industrial demand and valuation sensitivity.

**2. Fort Washington Investment Advisors Inc. OH Acquires 22,336 Shares of Linde PLC $LIN**
- Source: MarketBeat | 20251230T121032 | Somewhat-Bullish | Relevance: 100%
- Fort Washington Investment Advisors Inc. OH has increased its stake in Linde PLC by 26.3%, acquiring an additional 22,336 shares, bringing their total holdings to 107,360 shares valued at $50.996 million. Analysts maintain a "Buy" rating for Linde, with a target price of $501, despite some recent downgrades and price objective adjustments. The company reported strong Q3 earnings, beating consensus estimates, and recently announced a quarterly dividend of $1.50 per share.

**3. Medical Gas Market to Reach US$ 68.31 Billion by 2033 at 13.6%**
- Source: openPR.com | 20251230T120819 | Bullish | Relevance: 100%
- The global Medical Gas Market is projected to grow significantly, reaching US$ 68.31 billion by 2033 with a CAGR of 13.6% from its 2024 valuation of US$ 18.98 billion. This growth is primarily driven by increasing respiratory diseases, surgical procedures, and expanding healthcare infrastructure, with key players like Air Liquide and Linde plc dominating the market. North America currently leads with a 39% market share, highlighting strong regional demand and established healthcare systems.

**4. Linde's (NASDAQ:LIN) investors will be pleased with their notable 76% return over the last five years**
- Source: Simply Wall Street | 20251229T160819 | Somewhat-Bullish | Relevance: 100%
- Linde plc (NASDAQ:LIN) shareholders have seen a notable 76% total shareholder return over the last five years, outperforming its 64% share price return due to dividend payments. Despite a recent 11% dip in the last quarter, the company's compound earnings per share growth of 29% per year over the five-year period is impressive, suggesting the market may be viewing the company pessimistically given the share price gain of 10% over the same period. Significant insider buying in the last quarter also indicates positive sentiment from within the company.

**5. Annex Advisory Services LLC Raises Stake in Linde PLC $LIN**
- Source: MarketBeat | 20251229T081733 | Somewhat-Bullish | Relevance: 100%
- Annex Advisory Services LLC increased its stake in Linde PLC by 3.9%, acquiring an additional 3,217 shares to own a total of 86,228 shares valued at approximately $40.96 million. Despite some analysts trimming price targets, the consensus rating for Linde remains "Buy." The company exceeded Q3 EPS expectations and set a strong FY2025 guidance, offering a quarterly dividend of $1.50.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | RBC Capital | $490 | $540 | -9% |
| 2025-12-03 | CICC | $510 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | RBC Capital | main | Outperform |
| 2025-12-03 | CICC | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($1.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.2% (-0.1%)
- Blackrock Inc.: 7.6% (+0.3%)
- State Street Corpora: 4.0% (+0.9%)
- JPMORGAN CHASE & CO: 3.7% (+100.1%)
- FMR, LLC: 2.6% (+4.2%)

### Key Risks

1. Long-term trend broken: trading 5.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.93 elevated, pricing in significant growth expectations. Forward P/E 24.0x stretched relative to 9% growth. Quality metrics strong (margin 21%). Balance sheet: $1.7B free cash flow. Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $200.9B |
| Beta | 0.86 |
| 52W Range | $387.78 - $486.38 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.93 |
| Forward P/E | 24.0 |
| Current P/E | 26.1 |
| YoY Growth | 8.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.6% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Below SMA200 (0.94x), long-term trend not supportive. MACD histogram positive (2.65), confirming momentum. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.61% (CS: 76) | Neutral |
| RSI_14 | 62.1 | Neutral |
| MACD Histogram | 2.65 | Bullish |
| vs SMA20 | 1.036x | Above |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 0.945x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $428.36
- **Stop Loss:** $415.98 (2.9% risk)
- **Target:** $440.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $45,406.16
- **Portfolio %:** 45.41%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-05 (Est: $4.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.18 | $4.21 | +0.8% |
| 2025Q2 | $4.04 | $4.09 | +1.4% |
| 2025Q1 | $3.92 | $3.95 | +0.7% |
| 2024Q4 | $3.92 | $3.97 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*